Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respirato… Read more
Enanta Pharmaceuticals Inc (ENTA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.092x
Based on the latest financial reports, Enanta Pharmaceuticals Inc (ENTA) has a cash flow conversion efficiency ratio of -0.092x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.70 Million) by net assets ($126.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Enanta Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Enanta Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Enanta Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enanta Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ningbo Ocean Shipping Co. Ltd. A
SHG:601022
|
N/A |
|
Synektik S.A.
WAR:SNT
|
0.376x |
|
F.I.L.A. - Fabbrica Italiana Lapis ed Affini S.p.A
F:3S0
|
0.077x |
|
SNT Motiv Co Ltd
KO:064960
|
0.028x |
|
Qudian Inc
NYSE:QD
|
0.053x |
|
Tianyang Hot Mel
SHG:603330
|
0.078x |
|
GuangDong Leary New Material Technology Co. Ltd. A
SHG:688683
|
0.046x |
|
Electrosteel Castings Limited
NSE:ELECTCAST
|
0.072x |
Annual Cash Flow Conversion Efficiency for Enanta Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Enanta Pharmaceuticals Inc from 2011 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $64.72 Million | $-19.27 Million | -0.298x | +51.30% |
| 2024-09-30 | $128.81 Million | $-78.76 Million | -0.611x | -28.47% |
| 2023-09-30 | $216.74 Million | $-103.15 Million | -0.476x | -80.39% |
| 2022-09-30 | $321.33 Million | $-84.78 Million | -0.264x | -50.56% |
| 2021-09-30 | $399.43 Million | $-70.00 Million | -0.175x | -1226.35% |
| 2020-09-30 | $455.58 Million | $7.09 Million | 0.016x | -89.92% |
| 2019-09-30 | $462.49 Million | $71.42 Million | 0.154x | +108.05% |
| 2018-09-30 | $393.68 Million | $29.22 Million | 0.074x | -57.47% |
| 2017-09-30 | $301.68 Million | $52.65 Million | 0.175x | +31.57% |
| 2016-09-30 | $269.94 Million | $35.81 Million | 0.133x | -59.14% |
| 2015-09-30 | $236.16 Million | $76.67 Million | 0.325x | +139.18% |
| 2014-09-30 | $148.65 Million | $20.18 Million | 0.136x | +40.76% |
| 2013-09-30 | $110.47 Million | $10.65 Million | 0.096x | -81.27% |
| 2012-09-30 | $43.93 Million | $22.62 Million | 0.515x | +382.94% |
| 2011-09-30 | $-131.96 Million | $24.02 Million | -0.182x | -- |